These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31498767)

  • 1. ACE inhibitors and ARBs: Managing potassium and renal function.
    Momoniat T; Ilyas D; Bhandari S
    Cleve Clin J Med; 2019 Sep; 86(9):601-607. PubMed ID: 31498767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Oktaviono YH; Kusumawardhani N
    Acta Med Indones; 2020 Jan; 52(1):74-79. PubMed ID: 32291375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers.
    Mohamed Pakkir Maideen N; Balasubramanian R; Muthusamy S; Nallasamy V
    Curr Cardiol Rev; 2022; 18(6):e110522204611. PubMed ID: 35546745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension.
    Kovesdy CP; Appel LJ; Grams ME; Gutekunst L; McCullough PA; Palmer BF; Pitt B; Sica DA; Townsend RR
    Am J Kidney Dis; 2017 Dec; 70(6):844-858. PubMed ID: 29029808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.
    Kurnik D; Vesterman-Landes J; Bialik M; Katzir I; Lomnicky Y; Halkin H; Loebstein R
    Clin Ther; 2011 Apr; 33(4):456-64. PubMed ID: 21635991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
    Parikh RV; Nash DM; Brimble KS; Markle-Reid M; Tan TC; McArthur E; Khoshniat-Rad F; Sood MM; Zheng S; Pravoverov L; Nesrallah GE; Garg AX; Go AS
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006415. PubMed ID: 32873054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure medications: ACE-I/ARB and chronic kidney disease.
    Han H
    J Ren Nutr; 2013 Nov; 23(6):e105-7. PubMed ID: 24209897
    [No Abstract]   [Full Text] [Related]  

  • 15. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis.
    Caldeira D; David C; Sampaio C
    Am J Cardiovasc Drugs; 2012 Aug; 12(4):263-77. PubMed ID: 22587776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
    Bakris GL; Weir MR
    Arch Intern Med; 2000 Mar; 160(5):685-93. PubMed ID: 10724055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
    Mangrum AJ; Bakris GL
    Semin Nephrol; 2004 Mar; 24(2):168-75. PubMed ID: 15017529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries.
    Maciejewski ML; Hammill BG; Qualls LG; Hastings SN; Wang V; Curtis LH
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1015-22. PubMed ID: 26991354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
    Edwards NC; Steeds RP; Chue CD; Stewart PM; Ferro CJ; Townend JN
    Br J Clin Pharmacol; 2012 Mar; 73(3):447-54. PubMed ID: 21950312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Qiao Y; Shin JI; Sang Y; Inker LA; Secora A; Luo S; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    Mayo Clin Proc; 2019 Nov; 94(11):2220-2229. PubMed ID: 31619367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.